Cancer cells have natural defenses against a type of cell death called ferroptosis. This study mapped those defenses across 30 cancer types and found 18 that could be vulnerable to ferroptosis-based treatments. A new drug called N6F11 can destroy a key defense protein (GPX4) specifically in cancer cells while leaving immune cells unharmed — making bone cancer and brain tumors new treatment candidates. Another target, FSP1, shrank lung tumors by 80% in animal studies. Existing FDA-approved drugs (HDAC inhibitors like panobinostat) can eliminate cancer cells that survive initial treatment. Together, these findings provide a roadmap for matching specific cancers to their best ferroptosis treatment strategy.